Peer Reviewed Publication Provides Evidence for Iron Dysregulation as a Driver of Dry AMD/GA and the Potential of Transferrin to Restore Iron Balance, Reinforcing PulseSight’s Therapeutic Strategy for PST-611
PARIS, Oct. 14, 2025 (GLOBE NEWSWIRE) -- PulseSight Therapeutics, a clinical stage ophthalmology biotech company developing disruptive non-viral vectorized therapies with minimally-invasive delivery technology welcomes the publication of new data reinforcing interest in transferrin (Tf) as a drug candidate for the treatment of dry age-related macular degeneration (AMD), in a study performed by scientists from Inserm and Cochin Hospital in Paris, in collaboration with PulseSight’s scientists.